Progress and promise of CAR-T cell treatment in autoimmune diseases

Chimeric antigen receptor (CAR)-expressing cells hold immense potential for treating autoimmune diseases, despite the challenges that remain. Recent advancements have shown CAR cells to be capable of resetting dysfunctional immune systems, offering new hope for patients with autoimmune diseases. In autoimmune diseases, CAR-T cells can eliminate the entire pool of tissue B cells in affected organs, leading to a state of immune reset.

This deep depletion of B cells has been shown to result in sustained, drug-free remission of autoimmune diseases. CAR-T cell therapy has already been approved for treating certain types of B cell malignancies and has recently been used in treating systemic lupus erythematosus. Its potential extends beyond autoimmune diseases, with applications in neuroinflammatory disorders, immune-driven cytopenia, and inflammatory bowel disease.

CAR-T cell therapy offers several advantages, such as the ability to completely eliminate the B cell compartment and disrupt germinal center structures, which can induce immune homeostasis. Moreover, CAR-T cells have a lower risk of causing cytokine release syndrome, neurological side effects, and hematotoxicity compared to traditional treatments.

However, further research is needed to fully understand the long-term safety profile of CAR-T cell therapy, including the potential risks of late-onset neutropenia, persistent B cell aplasia, and the emergence of secondary malignancies. Additional questions remain regarding the necessity of eliminating long-lived plasma cells and the optimal lymphodepletion regimen for CAR-T cell therapy in autoimmune diseases.

Despite these challenges, CAR-T cell therapy shows great promise for transforming the care of patients with autoimmune diseases, providing deep and sustained drug-free remission and potentially lowering infection risk and making family planning easier.